



Notes to Editor

About AudioCure

AudioCure Pharma GmbH is a pharmaceutical R&D company with a focus on hearing disorders. The company was founded by Prof. Hans Rommelspacher, former head of the Department of Clinical Neurobiology in the Psychiatric Clinic at the Charité University, Berlin. He has vast experience in research on neuro-protection and treatments for neurodegenerative disorders. Dr. Reimar Schlingensiepen, COO, is a serial entrepreneur and manager of biopharmaceutical companies. He has initiated and led several deals within the high-tech industry. The team of specialists at AudioCure is dedicated to the preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear.

For further information please visit www.audiocure.de.

About High-Tech Gründerfonds

High-Tech Gründerfonds invests in young, high potential, high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping to market launch. Typically, High-Tech Gründerfonds invests 600.000 euros at the seed stage, with the potential for up to 2 million euros per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy and the KfW Banking Group as well as strategic corporate investors. High-Tech Gründerfonds has about 576 million euros under management in two funds (272 million euros HTGF I, 304 million euros HTGF II).

For further information please visit www.high-tech-gruenderfonds.de.

Contact

AudioCure Pharma GmbH

Dr. Reimar Schlingensiepen, COO
Phone: +49 30 2576179-98
E-Mail: pr@audiocure.de

High-Tech Gruenderfonds Management GmbH

Dr. Martin Pfister, Senior Investment Manager
Phone: +49 228 823001-00
E-Mail: info@high-tech-gruenderfonds.de